Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16747997 | 1.00 | NPY5R (0.45) | NPY5RSMN1; SMN2GAACYP1A2CYP2C9 | |
| SCHEMBL16747996 | 1.00 | NPY5R (0.45) | NPY5RSMN1; SMN2GAACYP1A2CYP2C9 | |
| SCHEMBL16745397 | 0.94 | L3MBTL1 (0.55) | NPY5RSMN1; SMN2GAACYP1A2CYP2C9 | |
| SCHEMBL16745414 | 0.92 | TP53 (0.46) | NPY5RSMN1; SMN2GAACYP1A2CYP2C9 | |
| SCHEMBL16745417 | 0.92 | TP53 (0.46) | NPY5RSMN1; SMN2GAACYP1A2CYP2C9 | |
| SCHEMBL16747888 | 0.86 | CYP1A2 (0.38) | NPY5RSMN1; SMN2GAACYP1A2CYP2C9 | |
| SCHEMBL16747882 | 0.86 | CYP1A2 (0.38) | NPY5RSMN1; SMN2GAACYP1A2CYP2C9 | |
| SCHEMBL16745425 | 0.72 | TP53 (0.46) | NPY5RCYP1A2CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL16747993 | 0.71 | JAK2 (0.48) | NPY5RCYP1A2CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL16747994 | 0.71 | TP53 (0.48) | NPY5RCYP1A2CYP2C9CYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9481662-B2 | Seriniquinones, melanoma-specific anticancer agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-01 | — | — | US | disclosed |
| US-20150148314-A1 | SERINIQUINONES, MELANOMA-SPECIFIC ANTICANCER AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148314-A1 | SERINIQUINONES, MELANOMA-SPECIFIC ANTICANCER AGENTS | SDHA, KLK3, BRDT | NPY5R 4677/4885SMN1; SMN2 2167/4885GAA 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.